| Sign In to gain access to subscriptions and/or personal tools. |
Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1aDepartment of Neurology, Mayo Medical and Graduate Schools, Rochester, MN 55905, USA, kumar.neeraj{at}mayo.edu
Department of Neurology and Immunology, Mayo Medical and Graduate Schools, Rochester, MN 55905, USA Background: Animal studies have shown that some human monoclonal antibodies promote myelin repair in models of demyelinating disease. Scleromyxedema is a dermatologic disorder associated with a monoclonal gammopathy and neurologic manifestations. The reason for occurrence of cutaneous reactio ns in interferon treated patients is unknown. Case description: A 37-year-o ld woman was started on weekly interferon beta-1a (IFN beta-1a) following a diagnosis of multiple sclerosis (MS). A fter having been on interferon therapy for three years, she developed skin lesions secondary to scleromyxedema. Her IFN beta-1a was discontinued and intravenous immunoglobulin therapy was started for her scleromyxedema. A t a six-month follow up, her skin lesions improved and there was no recurrence of neurologic symptoms. Conclusions: This is the first report of occurrence of scleromyxedema in a patient with MS. While this could be a chance association, it does raise the question if her neurologic manifestations could be secondary to scleromyxedema. Further research into the mechanism of IFN related cutaneo us side effects is needed. Evidence regarding the remyelinating nature of human monoclonal antibodies raises interest in the potential therapeutic role these antibodies may have.
Key Words: interferons • monoclonal antibodies • multiple sclerosis • scleromyxedema
Multiple Sclerosis, Vol. 10, No. 1,
85-86 (2004) This article has been cited by other articles:
|
|||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
